Chemo plus immunotherapy before surgery for cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer at a stage that can be surgically removed (stages IB3, IIA2, IIB, or IIIC1).
- You are 18 years or older and in good enough health to have surgery (ECOG performance status 0-1).
- You have not had any previous treatment for this cancer, including surgery, chemotherapy, radiation, or immunotherapy.
- Your blood counts and organ function (liver, kidneys, heart) are within a certain healthy range.
- You are not pregnant, breastfeeding, or have an active infection like hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests a new combination of chemotherapy and immunotherapy before standard chemoradiation for locally advanced cervical cancer. The goal is to see if adding immunotherapy first helps shrink the tumor and improve treatment outcomes.
This trial tests a new immunotherapy drug called cadonilimab combined with radiation therapy for people with locally advanced cervical cancer who cannot receive the usual chemotherapy due to age, kidney problems, heart issues, allergies, or personal choice.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemoradiation for cervical cancer that has spread to a few other places in the body. It aims to see if this combination can help control the cancer better.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.